Managing Partner, High Lantern Group
Drew Holzapfel is a Managing Partner at High Lantern Group, with experience in the federal government, pharmaceutical companies including Pfizer, The White House, and US Department of Health and Human Services. He has led initiatives with biopharma companies to advance market readiness, address policy issues, and build strategic partnerships. Drew’s work spans all areas in life sciences and includes significant specialization in Alzheimer’s, mental health, and neuroscience.
We use data collected by cookies to analyze traffic on this website. By clicking “Yes,” you agree to our use of cookies as described in our Privacy Policy.